The Gross Margin of Clovis Oncology Inc (CLVS) is
73.90%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2021-12-31 |
73.90%
|
| 2020-12-31 |
74.89%
|
| 2019-12-31 |
75.73%
|
| 2018-12-31 |
76.83%
|
| 2017-12-31 |
78.92%
|
| 2016-12-31 |
-
|
| 2015-12-31 |
-
|
| Ticker |
Name |
Value |
|
ACIU
|
AC Immune AG
|
7775.20%
|
|
AMGN
|
Amgen Inc
|
70.78%
|
|
EPZM
|
Epizyme Inc
|
71.95%
|
|
MRUS
|
Merus NV
|
7775.20%
|
|
SYRS
|
Syros Pharmaceuticals Inc
|
7775.20%
|
|
XBIT
|
XBiotech Inc
|
83.79%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
CMRX
|
Chimerix Inc
|
100.00%
|
|
HARP
|
Harpoon Therapeutics Inc
|
7775.20%
|
|
KDNY
|
Chinook Therapeutics Inc
|
7775.20%
|
|
SGTX
|
Sigilon Therapeutics Inc
|
7775.20%
|
|
GTHX
|
G1 Therapeutics Inc
|
91.28%
|
|
IDYA
|
IDEAYA Biosciences, Inc.
|
7775.20%
|
|
ANAB
|
AnaptysBio, Inc.
|
7775.20%
|
|
CNTG
|
Centogene NV
|
36.46%
|
|
KPTI
|
Karyopharm Therapeutics Inc.
|
95.93%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
KALV
|
KalVista Pharmaceuticals, Inc.
|
93.72%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
AGEN
|
Agenus Inc
|
99.11%
|
|
CTMX
|
CytomX Therapeutics, Inc.
|
7775.20%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
INBX
|
Inhibrx Biosciences Inc
|
7775.20%
|
|
JNCE
|
Jounce Therapeutics Inc
|
7775.20%
|
|
VYGR
|
Voyager Therapeutics, Inc.
|
7775.20%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
DVAX
|
Dynavax Technologies Corp
|
82.17%
|
|
MTEM
|
Molecular Templates Inc
|
7775.20%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
RIGL
|
Rigel Pharmaceuticals, Inc.
|
93.33%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
ADAP
|
Adaptimmune Therapeutics PLC
|
99.96%
|
|
AFMD
|
Affimed NV
|
83.70%
|
|
DTIL
|
Precision Biosciences, Inc
|
7775.20%
|
|
SURF
|
Surface Oncology Inc
|
7775.20%
|
|
VNDA
|
Vanda Pharmaceuticals Inc
|
93.96%
|